Mark H. Wessels
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 15, 2025
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis.
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: January 15, 2025
Serum neurofilament light and glial fibrillary acidic protein levels are not associated with wearing-off symptoms in natalizumab-treated multiple sclerosis patients.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: November 04, 2024
Impact of serum neurofilament light on clinical decisions in a tertiary multiple sclerosis clinic.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: October 18, 2024
Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament light.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: August 02, 2023
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS).
Journal: Journal of neurology, neurosurgery, and psychiatry
Published: June 29, 2023
Glial fibrillary acidic protein and multiple sclerosis progression independent of acute inflammation.
Journal: Multiple sclerosis (Houndmills, Basingstoke, England)
Published: June 15, 2023
Association between age and inflammatory disease activity on magnetic resonance imaging in relapse onset multiple sclerosis during long-term follow-up.
Journal: European journal of neurology
Published: January 27, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026